Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shattuck LabsSTTK -2.44%42 EV-to-EBITDA is -9.09 as of Sep. 05, 2026. GuruFocus rates STTK with a GF Score™ of 42/100 and a GF Value™ of $1.05 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 403 Biotechnology companies, Shattuck Labs ranks worse than 248138.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shattuck Labs's enterprise value is $474.83 Mil.
Shattuck Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-52.22 Mil. Therefore, Shattuck Labs's EV-to-EBITDA for today is -9.09.
The historical rank and industry rank for Shattuck Labs's EV-to-EBITDA or its related term are showing as below:
STTK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -64.42 Med: -0.91 Max: 2.15
Current: -9.09
During the past 8 years, the highest EV-to-EBITDA of Shattuck Labs was 2.15. The lowest was -64.42. And the median was -0.91.
STTK's EV-to-EBITDA is ranked worse than 100% of 403
companies
in the Biotechnology industry
Industry Median: 13.7
vs STTK: -9.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shattuck Labs's PE Ratio (TTM) for today is calculated as:
Shattuck Labs's share price for today is $6.78.
Shattuck Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Shattuck Labs's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Shattuck Labs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shattuck Labs EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shattuck Labs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shattuck Labs's EV-to-EBITDA falls into.
Shattuck Labs's current Enterprise Value is $474.83 Mil.
Shattuck Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-52.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shattuck Labs (STTK) has a EV-to-EBITDA of -9.09 as of Sep. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shattuck Labs. According to the industry distribution chart, Shattuck Labs ranks #999999 out of 403 companies in the Biotechnology industry.
Is Shattuck Labs' EV-to-EBITDA too high?
Shattuck Labs' current EV-to-EBITDA is -9.09. Based on the distribution chart, Shattuck Labs ranks #999999 out of 403 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shattuck Labs has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shattuck Labs' EV-to-EBITDA compare to BBOT and CTMX?
According to the Biotechnology industry distribution chart, Shattuck Labs ranks #999999 out of 403 companies for EV-to-EBITDA. This places Shattuck Labs in the lower half of its industry. The industry median EV-to-EBITDA is 13.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shattuck Labs. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shattuck Labs's current EV-to-EBITDA is -9.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shattuck Labs stock overvalued right now?
Based on GuruFocus' analysis, Shattuck Labs (STTK) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $6.78 — trading 545.7% above its estimated fair value. The current EV-to-EBITDA is -9.09. Shattuck Labs' overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shattuck Labs (STTK), the current EV-to-EBITDA is -9.09 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shattuck Labs (STTK) Overvalued in 2026?
Based on GuruFocus' analysis, Shattuck Labs stock appears to be overvalued.
The current stock price of $6.78 is trading 545.7% above its estimated GF Value™ of $1.05.
GuruFocus considers Shattuck Labs to be Significantly Overvalued.
Key valuation signals for STTK:
EV-to-EBITDA: -9.09
GF Value™: $1.05 vs. price of $6.78 (545.7% above fair value)
No single metric tells the full story. See the STTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
42GF Score
Get the complete analysis for STTK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STTK has been successfully added to your 
